Xponance Inc. Makes New Investment in Revvity, Inc. (NYSE:RVTY)

Xponance Inc. bought a new stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,939 shares of the company's stock, valued at approximately $1,742,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. KBC Group NV bought a new stake in Revvity in the 3rd quarter worth approximately $25,301,000. 2Xideas AG bought a new stake in Revvity during the 3rd quarter valued at $20,968,000. Citigroup Inc. purchased a new stake in Revvity in the third quarter worth about $5,548,000. Wesbanco Bank Inc. purchased a new position in Revvity during the third quarter valued at approximately $522,000. Finally, Headinvest LLC bought a new stake in Revvity during the third quarter valued at about $57,000. Institutional investors own 86.65% of the company's stock.

Revvity Stock Performance

Shares of NYSE:RVTY traded down $0.82 on Wednesday, reaching $102.68. The company's stock had a trading volume of 632,067 shares, compared to its average volume of 853,912. The stock's 50-day moving average is $104.74 and its two-hundred day moving average is $101.49. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $133.26. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. The stock has a market capitalization of $12.68 billion, a P/E ratio of 18.67, a PEG ratio of 2.62 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, topping the consensus estimate of $1.15 by $0.10. The company had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. As a group, sell-side analysts forecast that Revvity, Inc. will post 4.65 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity's dividend payout ratio is presently 5.09%.

Insider Activity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the transaction, the insider now owns 92,801 shares of the company's stock, valued at approximately $9,677,288.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on RVTY shares. Stifel Nicolaus increased their price objective on shares of Revvity from $95.00 to $110.00 and gave the company a "hold" rating in a research report on Friday, February 2nd. Barclays upped their target price on Revvity from $92.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. Evercore ISI upgraded shares of Revvity from an "in-line" rating to an "outperform" rating and upped their price objective for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Raymond James lifted their price target on shares of Revvity from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. Finally, UBS Group lowered Revvity from a "buy" rating to a "neutral" rating and boosted their price objective for the stock from $105.00 to $125.00 in a research note on Tuesday, January 16th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of "Moderate Buy" and an average target price of $118.91.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.